id	等位基因	注释文本
934	*36	The CYP2D636 allele is assigned as a no function allele by CPIC. Patients carrying the 36 allele in combination with another no function allele, a normal function allele or a decreased function allele with an activity value of 0.25 may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.
933	*21	The CYP2D621 allele is assigned as a no function allele by CPIC. Patients carrying the 21 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.
932	*10	The CYP2D610 allele is assigned as a decreased function allele with an activity value of 0.25 by CPIC. Patients carrying the 10 allele in combination with a no function allele or another decreased function allele with an activity value of 0.25 may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.
931	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.
930	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with another no function or a normal function allele may have lower clearance of flecainide as compared to patients carrying alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.
929	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have higher clearance of flecainide as compared to patients carrying two no function alleles; two decreased function alleles with an activity value of 0.25; or a no function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence flecainide metabolism. This annotation only covers the pharmacokinetic relationship between CYP2D6 and flecainide and does not include evidence about clinical outcomes.

id	证据的ID	总结
2792	1183621673	CYP2D6 5/36 + 10/10 + 10/36 + 21/36 are associated with decreased oral clearance (CL/F) of flecainide in patients with supraventricular tachyarrhythmia when treated with flecainide as compared to CYP2D6 1/1 + 1/2.
2791	1183621590	CYP2D6 4 + 5 + 10 + 21 + 36 are associated with increased age-related decline in flecainide clearance patients treated with oral flecainide for supraventricular tachyarrhythmias when treated with flecainide as compared to CYP2D6 1.
2790	1183621641	CYP2D6 10 is not associated with pharmacokinetics of flecainide in healthy Chinese subjects when exposed to flecainide in healthy individuals as compared to CYP2D6 1.
2789	1448099915	CYP2D6 normal metabolizer genotype is associated with concentrations of flecainide in people with Tachycardia, Supraventricular as compared to CYP2D6 poor metabolizer and intermediate metabolizer genotypes.
2788	PA166104969	Annotation of DPWG Guideline for flecainide and CYP2D6

id	类型	评论
644	Update	Edited phenotype descriptions to fit LOE 1A template
643	Update	Added DPWG guideline as evidence. LOE changed to 1A.
642	Update	CA score added as part of scoring system release. LOE assigned following curator review.
641	Update	fixed typo in text
640	Update	Updated OMB race to appropriate biogeographical group

最新招商产品更多>>